Fluticasone detailed information

Jump to: navigation, search
Fluticasone detailed information
Fluticasone svg.png
Clinical data
Pregnancy
category
  • C for Intranasal and Inhaled
Routes of
administration
Intranasal, Inhaled, Topical Cream or Ointment
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability0.51% (Intranasal)
Protein binding91%
MetabolismIntranasal
Hepatic (CYP3A4-mediated)
Elimination half-life10 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H27F3O4S
Molar mass444.508 g/mol

WikiDoc Resources for Fluticasone detailed information

Articles

Most recent articles on Fluticasone detailed information

Most cited articles on Fluticasone detailed information

Review articles on Fluticasone detailed information

Articles on Fluticasone detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fluticasone detailed information

Images of Fluticasone detailed information

Photos of Fluticasone detailed information

Podcasts & MP3s on Fluticasone detailed information

Videos on Fluticasone detailed information

Evidence Based Medicine

Cochrane Collaboration on Fluticasone detailed information

Bandolier on Fluticasone detailed information

TRIP on Fluticasone detailed information

Clinical Trials

Ongoing Trials on Fluticasone detailed information at Clinical Trials.gov

Trial results on Fluticasone detailed information

Clinical Trials on Fluticasone detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fluticasone detailed information

NICE Guidance on Fluticasone detailed information

NHS PRODIGY Guidance

FDA on Fluticasone detailed information

CDC on Fluticasone detailed information

Books

Books on Fluticasone detailed information

News

Fluticasone detailed information in the news

Be alerted to news on Fluticasone detailed information

News trends on Fluticasone detailed information

Commentary

Blogs on Fluticasone detailed information

Definitions

Definitions of Fluticasone detailed information

Patient Resources / Community

Patient resources on Fluticasone detailed information

Discussion groups on Fluticasone detailed information

Patient Handouts on Fluticasone detailed information

Directions to Hospitals Treating Fluticasone detailed information

Risk calculators and risk factors for Fluticasone detailed information

Healthcare Provider Resources

Symptoms of Fluticasone detailed information

Causes & Risk Factors for Fluticasone detailed information

Diagnostic studies for Fluticasone detailed information

Treatment of Fluticasone detailed information

Continuing Medical Education (CME)

CME Programs on Fluticasone detailed information

International

Fluticasone detailed information en Espanol

Fluticasone detailed information en Francais

Business

Fluticasone detailed information in the Marketplace

Patents on Fluticasone detailed information

Experimental / Informatics

List of terms related to Fluticasone detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Fluticasone propionate is a potent synthetic corticosteroid often prescribed as treatment for asthma and allergic rhinitis. It is marketed with the brand names Flixotide and Flixonase by Allen & Hanburys, and Flovent, and Flonase by GlaxoSmithKline. GlaxoSmithKline also markets a combination of fluticasone and salmeterol as Advair (US) or Seretide (UK).

It is also used as a cream or ointment for the treatment of eczema and psoriasis (Cutivate UK).

How it works

Inflammation is recognized as an important component in the pathogenesis of asthma. Glucocorticoids have been shown to inhibit multiple cell types (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and mediator production or secretion (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in the asthmatic response. These anti-inflammatory actions of glucocorticoids may contribute to their efficacy in asthma. Typically, however, the action on the cells affected requires several days. Therefore, inhaled steroids are not used for immediate relief of asthma, but instead as preventive and maintenance therapy.

Nasal spray

Dosage

  • Adults: The recommended dosage for adults is 100 micrograms (two sprays) into each nostril once daily. This may be increased to maximum of twice daily use if required. When control is achieved dose is reduced to 50 micrograms (one spray) to each nostril daily.
A canister of Flovent in the inhaler.
  • Adolescents and children: The recommended dosage for children (4 years of age or older in US, but only from 12 years in UK) is 50 micrograms (one spray) into each nostril once daily. This may be increased to maximum of twice daily use if required.

Flonase patent issues

GlaxoSmithKline's patent on Flonase expired in May 2004. The Food and Drug Administration (FDA) approved the sale of a generic version of Flonase on February 22, 2006. On February 23, 2006, GlaxoSmithKline (GSK) was able to obtain a temporary 10-day restraining order from a federal judge in Baltimore blocking the shipment and sales of the approved generic versions of Flonase. The restraining order lasted until March 6, 2006. The basis of the complaint by GSK was that the FDA failed to follow its own regulations in approving the generics and failed to apply the same quality standards for the generic version as it did for Flonase. GSK made these arguments in petitions filed with the FDA, but the FDA rejected those petitions. The Maryland District Court denied the request by GSK to extend the ban on Flonase generics beyond March 6, 2006, and GSK released a statement that they would not appeal the ruling.[2] The ruling meant that sales of generic versions of Flonase could proceed.

References

Clinical trials

This listing is NOT complete and should NOT be construed as support for treatment decisions. See also PubMed clinical manuscripts referring to fluticasone

  • Burge P, Calverley P, Jones P, Spencer S, Anderson J, Maslen T (2000). "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial". BMJ. 320 (7245): 1297–303. PMID 10807619.
  • Paggiaro P, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J (1998). "Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group". Lancet. 351 (9105): 773–80. PMID 9519948.
both support a positive outcome for use of fluticasone in patients with chronic obstructive pulmonary disease, also referred to as COPD

External link

hu:Flutikazon


Linked-in.jpg